In a bid to enter the protein degradation space, Amgen has entered intoa strategic research collaboration with Plexium to identify and develop targeted protein degradation therapies for historically challenging drug targets. Amgen and Plexium will leverage the latter’s platform to discover molecular glues and monovalent degraders to bring two proteins together to induce degradation. The deal comes just three weeks after Amgen announced its collaboration with Arrakis Therapeutics to develop targeted RNA degraders.